Twenty years ago, President Bill Clinton announced completion of what was arguably one of the greatest advances of the modern era: the first draft sequence of the human genome.
"Without a doubt, this is the most important, the most wondrous map ever produced by humankind," Clinton said on June 26, 2000 from the White House, predicting that genome science "will revolutionize the diagnosis, prevention and treatment of most, if not all, human diseases." In the future, he said, "doctors will increasingly be able to cure diseases like Alzheimer's, Parkinson's, diabetes, and cancer by attacking their genetic roots."
And indeed, the sequencing of the human genome achieved simultaneously by the Human Genome Project (HGP), an international consortium begun in 1990 and led by Francis Collins, MD, then director of the National Human Genome Research Institute, and by J. Craig Venter, PhD, with his team at the privately held Celera Genomics has revolutionized the approach to human health.
President Bill Clinton is flanked by Dr J. Craig Venter (left) and Dr Francis Collins announcing the first draft sequence of the human genome in June 2000.
Although the unbridled optimism of 20 years ago has not been matched with success in every quarter, much of the promise has begun to be realized. Scientists have so far identified 5000 rare diseases and 40 to 50 genes that confer cancer risk, developed simple prenatal blood tests to detect chromosomal abnormalities, and generated genetic profiles of tumors to facilitate better-targeted therapies, among other accomplishments. Even the current global fight against COVID-19 is relying on genomics.
"There hasn't been a pharmaceutical developed in last 20 years that hasn't utilized genome information," Venter told Medscape Medical News.
"Not a day goes by in science that we don't see some offshoot of benefit from what happened 20 years ago," said Eric Topol, MD, the chair of innovative medicine at Scripps Research in La Jolla, California, and Editor-in-Chief of Medscape.
Finding the genes was just the beginning though; describing function and using that information therapeutically is still just getting underway in many clinical areas. "We now know that genes are only a small fraction of the complexity of the human genome," says Eric Green, MD, PhD, the current director of the National Human Genome Research Institute (NHGRI).
When it started, the sequencing of the human genome did not seem like a value proposition nor was it expected to be. Congress authorized $3 billion for the HGP in 1990 and set a target completion date of 2005.
The final sequence, a database of some 3 billion DNA base pairs, came in under budget the NHGRI estimates the cost at $2.7 billion in 2003, two years ahead of schedule and exactly 50 years after James Watson and Francis Crick first described DNA.
It had been only 15 months since the international consortium of 1000 researchers across six nations began their sequencing effort in earnest, and a scant 9 months from when Venter's team starting sequencing its human genome. Celera Genomics spent just $100 million, Venter estimates.
What seemed like a massive investment at the time now looks like chicken scratch. "It was a bargain," Topol said.
The race to create the map of the human genome would generate goodwill, create strife, elevate egos, and make careers. Much has been written about the clash between Collins and Venter two polar opposites with different motivations and different approaches.
Collins, a dedicated public servant and man of deep Christian faith, believed in the power of the academic and governmental research enterprise.
Venter, on the other hand, ruffled feathers with his big ideas and generally more capitalistic approach. He began his career at the National Institutes of Health (NIH) in 1984 and created a gene discovery tool called expressed sequence tags (ESTs). That caught the eye of venture capitalists, who lured him out of the agency. They backed Venter's nonprofit, The Institute for Genomic Research (TIGR), to develop the technology.
At TIGR, Venter decoded the genome of Haemophilus influenzae using his whole genome "shotgun" technique. When he applied to the NIH for a grant to support the shotgun method, however, he was rejected. The maker of a DNA sequencing machine, PE Biosystems, then installed Venter as the CEO of the new, private Celera Genomics in 1998.
The NIH-led consortium did not see the value of the shotgun approach and instead relied on a more traditional sequencing method, which was more laborious and time-consuming, Topol recalls. After that NIH rejection, the competition was on, and the rivalry became bitter.
"There was no love lost between these two gentleman," Topol acknowledged. On that day in June 2000 when the announcement was made, "it required Clinton and whoever else to kind of get them to stand together and make nice," added Topol, who was present at the celebration.
A release from the NIH on the commemoration of the 20th anniversary in June of this year describes the situation this way: "The joint presence of these two scientific leaders signified the agreed-upon shared success of the public HGP and private Celera Genomics efforts in generating the first draft sequence of the human genome."
Still, the competition, in retrospect, was a good thing because it accelerated progress, Topol said.
The draft sequence unveiled in 2000 covered 90% of the genome at an error rate of one in 1000 base pairs, but there were more than 150,000 gaps, and only 28% of the genome had reached true completion. When the final version was made public in 2003, there were less than 400 gaps and 99% of the genome was finished with an accuracy rate of less than one error in every 10,000 base pairs.
Looking back, the technologies used then "now seem almost prehistoric," says NHGRI director Green. "Nothing in the way we sequence DNA is the same now. We can do it in a day or two and it costs less than a thousand dollars." He expects the cost of sequencing a human genome will eventually drop below $100.
The final, almost-complete sequence published in 2003 was "foundational," providing "the alphabet around which everything else has been constructed," said Mark McCarthy, MD, senior director and staff scientist in human genetics at the California-based biotechnology company, Genentech. "It's hard to think of a more concrete example in science other than maybe the periodic table," McCarthy told Medscape Medical News.
Doing genetic research before the full sequence was published, he says, was like being an "explorer in some novel land." Without a clear map of the terrain, researchers used analogue methods to try to determine locations of genes or recombination events, he said. It was frustrating and "a huge impediment to progress."
Now, scientists can "just click on a mouse and get almost immediately the worlds of data around any genomic regions," he said.
"Most scientists today never had to sequence a gene," Venter points out. "They don't have to, because they just look it up on the internet."
"Graduate students today can't imagine how we ever did any experiments or learned anything without having access to the human genome sequence with a click of a mouse," said Collins, in a video testimonial celebrating the 30th anniversary of the start of the project.
To Collins, one of the genome project's main goals was to give clinicians better tools to heal their patients. "Together we must develop the advances in medicine, that is the real reason for doing this work," he said in 2000.
If you would have told me that in my professional career I would have seen genomics actually change the practice of medicine in any way, shape, or form, I would have said, 'There's just no way, we're two generations away from that.' Dr Eric Green, director of the National Human Genome Research Institute
But it wasn't until a decade later that genomics was talked about in medicine, said Green. "Now, we have clear examples for genomics being used every day," he said.
"If you would have told me that in my professional career I would have seen genomics actually change the practice of medicine in any way, shape or form, I would have said, 'There's just no way, we're two generations away from that,'" Green said.
Perhaps the biggest impact of these advances in genomics to date has been in the practice of oncology.
"Cancer care has been one of the biggest beneficiaries of the genomic revolution," said Frederick M. Schnell, MD, chief medical officer of the Community Oncology Alliance (COA). Schnell points to the work of Brian Druker, MD, who helped discover the mutation that causes chronic myelogenous leukemia and also was instrumental in developing a precision treatment for CML, imatinib (Gleevec).
"That was probably the singular most important development for a particular, albeit not common, but not uncommon disease that had a disgraceful, horrible projected survival and mortality associated with it, and has changed it to a curable disease," Schnell told Medscape.
The HGP led to the Cancer Genome Atlas, a book of some 20,000 cancer genomes and matched normal samples spanning 33 cancer types.
"In order to understand what was going wrong in a cancer, you first had to understand what the genome was supposed to look like in somebody the cell that was not cancerous," said Richard Schilsky, MD, chief medical officer and executive vice president of the American Society of Clinical Oncology (ASCO).
The comparisons "help us identify mutations that are real drivers of cancer and have opened up the whole field of precision oncology," Schilsky, formerly chief of hematology/oncology and deputy director of the University of Chicago Comprehensive Cancer Center, told Medscape Medical News.
In addition to helping identify cancer susceptibility genes, the genome project also led to variations associated with how drugs are metabolized, Schilsky said.
For instance, it is now known that 10% of the population has a variant of the UGT1A1 gene that leads to poor metabolism of the chemotherapy drug irinotecan (Camptosar), causing worse side effects. The drug's label now notes the availability of a simple lab test to look for the variant.
Schilsky is lead investigator of an ASCO-sponsored trial called TAPUR that aims to match patients with certain tumor variants to therapies that might work, but are not FDA-approved for that particular cancer. Some 2000 individuals have enrolled and received free medications (provided by one of the eight drug companies participating) since the trial began in 2016, said Schilsky.
One goal is to collect evidence on off-label uses which might help therapies gain acceptance in clinical practice guidelines and, potentially, reimbursement. TAPUR also aims to help oncologists learn more about genomics.
Precision oncology is still not available to all cancer patients, however. Schnell said the COA is lobbying for better access and insurance coverage.
He believes that genomics could be used as a replacement for screening tests such as mammograms and colonoscopies. "This is going to be a big application point for the genomic revolution as it continues," he said.
Topol agrees that genomics could create a tailored approach to prevention. "Why does every woman need a mammogram when only 12% will ever develop breast cancer?" he says.
The progress made to date in understanding the human genome is also proving to be a key weapon as scientists fight the important current threat of the COVID-19 pandemic.
China made the first genetic sequence of the SARS-CoV-2 virus available on January 12, 2020, just weeks after the nation reported the initial cluster of cases.
Researchers have since uploaded 245,000 genomic sequences of the SARS-CoV-2 virus to the World Health Organization's Global Initiative on Sharing All Influenza Data (GISAID) portal. The speedy sequencing and widespread sharing of data led to quick development of molecular diagnostics and identification of potential targets for vaccines and therapeutics.
The NHGRI, among others, is supporting genomic studies around the world that aim to understand the differences between those who become severely ill and those "who barely seem to notice they have the disease," NHGRI director Green told Medscape Medical News. "There is no question there is going to be some genomic basis for the severity of the disease,"
He also expects genomics to be used in vaccine trials to separate responders from nonresponders.
While rare monogenic diseases were a relative cinch, common illnesses like hypertension, diabetes, and Alzheimer's disease have turned out to be more complicated.
It wasn't until the mid-2000s, when genome-wide association studies (which look for small variations that occur more frequently in people with disease) came into greater use, that scientists began to get a clearer picture, said Genentech's McCarthy.
It turns out that "hundreds, if not thousands of genetic variations and genetic regions" seem to predispose someone to a common disease, he said. He's applying genome-wide approaches in type 2 diabetes, but it requires datasets of a million or more people to get a robust result, McCarthy said.
Even then, "it just gives you a bunch of sign posts around the genome and then you have to work out what they do and how they influence predisposition in a given individual," he said. Researchers have begun to understand "the range of pathways and networks that are involved in the genetic predisposition to type 2 diabetes," which in turn is giving information on potential therapeutic targets.
The obstacle is not having enough genome-wide genetic data, which may change as more countries find ways to collect more genetic data, McCarthy said.
"We're not getting complete comprehensive views of all the genes involved and all the genomic variants that confer risk," for chronic diseases, agreed Green. "That's the big challenge for the next decade."
Another challenge that NHGRI has outlined in its strategic plan, released in October, is broadening human genome reference databases to include a wider representation of humanity. "Much like all other scientific disciplines, genomics is reckoning with systematic injustice and biases of the past," the agency said in a press release. The plan also addresses data control, privacy, genome editing, and barriers to a thriving genomics enterprise.
Venter believes that getting to the root of chronic diseases means combining the phenotype with the genotype. In 2013, he started Human Longevity, a company that offers sequencing, imaging, and a host of diagnostics to those who can afford the service, to give a complete picture.
"Without extensive phenotype information, the genome isn't highly useful on its own," said Venter, who feels the combination could be a true preventive medicine platform.
As much as the sequencing of the genome has brought to medicine, "I think the greatest promise of the genome remains to be realized," said Venter.
The initial focus was on genes. Humans, it turns out, have only 20,000 genes, not that many more than worms or fruit flies. But there's more to life outside of those genes, said Green.
The human genome "is a treasure chest, but we have only gotten a limited number of the keys so far," said Topol. "It is not nearly as informative as it could be."
And genomics still has the potential to do harm an issue that gets periodic scrutiny by commissions and the public. On that day in 2000 at the White House, Venter noted that a just-released poll had reported that 46% of Americans believed that "the impact of the Human Genome Project will be negative."
Privacy of genetic information is a perennial concern, and technologies such as gene editing, which allows scientists to alter DNA have brought up new ethical challenges.
On the other hand, the public has been mesmerized by genetic genealogy technologies that allow them to determine their own ancestry or disease risk, and that have more recently helped law enforcement solve crimes, some of them longstanding cold cases.
Twenty years ago, Venter predicted that the wonders would continue unabated. "The complexities and wonder of how the inanimate chemicals that are our genetic code give rise to the imponderables of the human spirit should keep poets and philosophers inspired for the millenniums," he said in 2000.
His view is more tempered today. "I'm optimistic about the future," says Venter now. "I'm pessimistic about how soon it will get here."
For more Medscape Neurology news, join us on Facebook and Twitter
Original post:
The 'Wondrous Map': Charting of the Human Genome, 20 Years Later - Medscape
- Pandemic Lessons in Improving the Medical System - The New York Times - February 14th, 2021
- The Role of Hormones in Immunocompetence - Anti Aging News - February 14th, 2021
- Do Short People Live Longer? What We Know - Healthline - February 1st, 2021
- Hereford Thrives In Uncertain Year - Drovers Magazine - February 1st, 2021
- Women's Menstrual Cycles Tied to Moon's Phases - HealthDay News - February 1st, 2021
- Is The Full Moon Affecting Your Sleep and Flow? - Longevity LIVE - Longevity LIVE - February 1st, 2021
- Calico Purring Right Along With Life Extension Research - Nanalyze - February 1st, 2021
- Dr. William Kelley inducted into IAOTPs Hall of Fame - PRUnderground - February 1st, 2021
- Baptist Health of Northeast Florida Joins Forces with Blue Zones to Begin Building a Plan for Well-Being Transformation in Jacksonville - PR Web - February 1st, 2021
- Is longevity determined by genetics?: MedlinePlus Genetics - January 25th, 2021
- Optogenetics Shows How the Microbiome Affects Longevity - January 25th, 2021
- 9 Factors That Affect Longevity | ThinkAdvisor - January 25th, 2021
- Hereford thrives in an uncertain year | Farm Forum | aberdeennews.com - AberdeenNews.com - January 25th, 2021
- Njonjo, Moody Awori: Why these wazee are still up and running - The Standard - January 25th, 2021
- Son reported father to FBI weeks before he reportedly stormed the Capitol - Yahoo News - January 25th, 2021
- Study of More Than 1 Million People Finds Intriguing Link Between Iron Levels And Lifespan - ScienceAlert - January 5th, 2021
- Hereford Thrives in an Uncertain Year - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - January 5th, 2021
- Covid-19 Update Precision Medicine Software market: Poised to Garner Maximum Revenues by 2027 with major key players in the market Syapse, Allscripts,... - January 5th, 2021
- The New Anti-Ageing: How the pandemic unlocked new ways to lower your biological age - Telegraph.co.uk - January 5th, 2021
- A Good Age: Auld lang syne to the eldest who inspired and entertained us - The Patriot Ledger - January 5th, 2021
- Survival Of The Kindest: A New Mantra To Rebuild The Global Economy - Forbes - January 5th, 2021
- The Nashville bombing suspect sent packages to people across the country containing typed conspiracy theories about September 11 and lizard people,... - January 5th, 2021
- How does the human body react to being in space? - Sciworthy - December 24th, 2020
- A century and counting: Ardmore woman turned 100 on Friday - Daily Ardmoreite - December 24th, 2020
- The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 - PharmiWeb.com - December 24th, 2020
- Getting to the root of why hair goes gray - messenger-inquirer - December 24th, 2020
- Which countries have the highest life expectancy in Europe? - World Economic Forum - December 17th, 2020
- New Research Aims To Increase Longevity Of Bumblebee Hives For NZ Growers - Scoop.co.nz - December 17th, 2020
- Size Matters, And Other Lessons From Medical Genetics - Genomes Unzipped - December 17th, 2020
- Intermittent Fasting Not Working? Here's What Could Be Going Wrong, By an RD - The Beet - December 17th, 2020
- Hair loss treatment: Sandalwood and sandalore are both effective in increasing hair growth - Express - December 17th, 2020
- These are the signs and symptoms of dementia - and the stages explained - Yorkshire Post - December 17th, 2020
- Manahawkin Woman 'Scales' 100 Years With Service, Strength and Determination - The SandPaper - December 17th, 2020
- 15 Things To Stop Doing If You Want To Live To 100 - Longevity LIVE - Longevity LIVE - December 4th, 2020
- Ticking the boxes in a rain-fed dairy system - Dairy News Australia - December 4th, 2020
- Barack Obama On Who Is The GOAT Between LeBron James And Michael Jordan: 'LeBron James Is Not Quite There. We Don't Know How Many More Rings He Might... - December 1st, 2020
- 20 Dog Breeds That Live the Longest - Reader's Digest - December 1st, 2020
- Mutations of the coronavirus do not appear to make the virus more infectious, study says | TheHill - The Hill - November 30th, 2020
- Precision Medicine Software Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top... - November 30th, 2020
- Spaceflight does some weird things to astronauts bodies - MIT Technology Review - November 30th, 2020
- Genetics and Alcohol Use Disorder: 5 Things You Should Know - Longevity LIVE - November 7th, 2020
- Adrenomyeloneuropathy Treatment Market Covid-19 Impact On In-depth Industry Analysis: Ascend Biopharmaceuticals, Immatics Biotechnologies, Human... - November 7th, 2020
- Global AI Medicine Software Market Analysis of Key Players, Type, Application, Demand and Consumption By 2026 - Stock Market Vista - November 7th, 2020
- Global Obesity Treatment Market Incredible Potential Examined in New Research Report - The Think Curiouser - November 7th, 2020
- Global Adrenomyeloneuropathy Treatment Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -... - November 7th, 2020
- Early Evidence Shows Fasting, Keto Diet May Make Chemo and Some Other Cancer Treatments More Effective and Easier to Tolerate - Curetoday.com - November 7th, 2020
- Healthcare Business Process Outsourcing Market 2020 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2025 - Zenit... - November 7th, 2020
- Turning the Tide - Lifestyle Medicine and change (part 7) - South Coast Herald - October 25th, 2020
- Biohacking Conference Kyiv about Efficient Health Optimization Techniques to Take Place on November 11 - Interfax-Ukraine - October 25th, 2020
- Global Precision Medicine Software Market 2020 Recovering From Covid-19 Outbreak|Know More About Brand Players - The Think Curiouser - October 25th, 2020
- What's Behind All the Pro-Azerbaijan Articles? - Armenian Weekly - October 25th, 2020
- Global Precision Medicine Software Market (COVID-19 Analysis) Industry Share, Growth, Trends Analysis Report 2020-26 - The Think Curiouser - October 25th, 2020
- AI Medicine Software Industry Market Outlook | Development Factors, Latest Opportunities and Forecast 2025 - The Think Curiouser - October 25th, 2020
- Flint children exposed to lead suffer from dental problems, learning disabilities, other issues - MLive.com - October 25th, 2020
- The Importance of Deep Water in Fall Bass Fishing - Wired2Fish - October 25th, 2020
- Genomic Biomarker Market Growth, Demands, CAGR, Sales Volume, Opportunities, Types, Applications and Forecast up to 2023 - The Think Curiouser - October 25th, 2020
- Does Family History Of Diabetes Mean That I Will Inherit It Too? - NDTV Doctor - October 25th, 2020
- Genomic Biomarker Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Bio-Rad, Beckman Coulter, Myriad Genetics,... - September 28th, 2020
- Precision Medicine Software Market by Trends, Dynamic Innovation in Technology and 2025 Forecasts | Covid-19 Analysis - The Daily Chronicle - September 28th, 2020
- Losing hair fast? Applying this natural solution to the scalp resulted in new hair growth - Express - September 28th, 2020
- Lenny Kravitz on His Signature Scent, His Beach Beauty Routine, and the Secret to His Longevity - Vogue - September 24th, 2020
- How to Live Longer: A Look at the Science Behind the Longevity Movement - Vogue - September 22nd, 2020
- Healthy Aging Month observed nationwide in September - News - The Hutchinson News - September 22nd, 2020
- Massive Growth in Precision Medicine Software Market to Witness Robust Expansion by 2026 with Top Key Players like Syapse, Allscripts, Qiagen, Roper... - September 22nd, 2020
- Guest opinion: Why accessible health care is not government takeover - Deseret News - September 15th, 2020
- Development of heat-resistant cattle in the U.S. - Post Register - September 15th, 2020
- Viking genetics and robots working together at Alderston Mains - The Scottish Farmer - September 13th, 2020
- Nutrition and the Wisdom of Ethnic Cuisine: A Japanese Doctor's Perspective - Nippon.com - September 13th, 2020
- Anti-Aging and Prolonging Life By John Robert Cardillo - Health News Tribune - August 13th, 2020
- Environmental legislation to be biggest limiting factor for NI dairying in 2030 - Agriland.co.uk - August 13th, 2020
- Healthy ageing.. The eight R's - Daijiworld.com - August 13th, 2020
- The Secret to a Long, Healthy Life Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 10th, 2020
- What We Can Learn About Longevity From SuperAgers and Centenarians - Next Avenue - August 10th, 2020
- How to live longer - the anti-ageing spice to protect against an early death and cancer - Express - August 10th, 2020
- Global Precision Medicine Software Industry Market 2020 Size, Share, Trends, Growth and Outlook with Company Analysis and Forecast to 2025 - CueReport - August 10th, 2020
- Precision Medicine Software Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026... - July 12th, 2020
- Precision Medicine Software Market (impact of COVID-19) Growth, Overview with Detailed Analysis 2020-2026| Syapse, Allscripts, Qiagen, Roper... - July 12th, 2020
- Global Precision Medicine Software Market Analysis and Forecast 2027- including drivers, constraints, intimidation, challenges, opportunities, and... - July 11th, 2020
- Research On Global Genomic Biomarker Market (impact of COVID-19) with Top Players: Bio-Rad,Beckman Coulter,Myriad Genetics and Others - Owned - July 11th, 2020
- New Report: and China Genomic Biomarker Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and... - July 11th, 2020